Shanghai Fosun, China Fund Buy Nearly All Of Israel's Alma Lasers
This article was originally published in PharmAsia News
Shanghai Fosun Pharmaceutical and Primaerica-Fosun Fund jointly acquired nearly all of Israel's Alma Lasers, maker of medical lasers, primarily for cosmetic treatments.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.